Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the appointment of Manja Boerman, Ph.D., to the role of President, Cell & Gene Therapy, effective June 1, 2020.
April 30, 2020
· 7 min read